Alberto
Borobia Pérez
Alberto Borobia Pérez-rekin lankidetzan egindako argitalpenak (6)
2022
-
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494
2021
-
Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling
Clinical Pharmacokinetics, Vol. 60, Núm. 2, pp. 261-270
-
Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery
Clinical Therapeutics, Vol. 43, Núm. 5, pp. e86-e102
2020
-
Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects
Clinical Drug Investigation, Vol. 40, Núm. 7, pp. 617-628
-
Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates
Biomedicines, Vol. 8, Núm. 4
2019
-
Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population
International Journal of Antimicrobial Agents, Vol. 54, Núm. 4, pp. 463-470